{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:00:57Z","timestamp":1788354057454,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1014021","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000}}],"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-002562"],"award-info":[{"award-number":["INV-002562"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PP00P3_170702"],"award-info":[{"award-number":["PP00P3_170702"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PP00P3_203450"],"award-info":[{"award-number":["PP00P3_203450"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>\n                    Vaccines, monoclonal antibodies, and long-acting injectables are being developed to prevent\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    malaria. These therapeutics may target multiple stages of the parasite life cycle; evidence is needed to articulate their benefits with chemoprevention and prioritise candidates for clinical development. We used an individual-based malaria transmission model to estimate the health impact of combining new therapeutics with seasonal malaria chemoprevention (SMC). Our modelling framework used emulator-based methods with models of pre-liver and blood stage therapeutic dynamics. We evaluated the benefit of combining therapeutics with SMC in children under five by estimating reductions in the cumulative incidence of uncomplicated and severe malaria, relative to SMC or the new therapeutic alone, during and five years after deployment. Results showed that new therapeutics may require extended pre-liver stage duration or multi-stage activity to combine with SMC. For three SMC cycles in a high transmission setting, a pre-liver stage therapeutic with partial initial efficacy (&gt;50%) required a protection half-life &gt;230 days to reduce cumulative severe cases by &gt;23% during interventions, and &gt;5% five years after deployment stopped. Longer protection was needed when combined with four or five SMC cycles. And, combining SMC with a multi-stage therapeutic increased public health impact both during and after deployment. These results indicate that combining SMC with malaria therapeutics active against multiple stages of the parasite life cycle can improve the effectiveness of SMC, and highlight the need for clinical development to prioritise multi-stage therapeutics for improved malaria prevention in children.\n                  <\/jats:p>","DOI":"10.1371\/journal.pcbi.1014021","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:42:52Z","timestamp":1772131372000},"page":"e1014021","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combining seasonal malaria chemoprevention with novel therapeutics for malaria prevention: a mathematical modelling study"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-0053","authenticated-orcid":true,"given":"Lydia","family":"Braunack-Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3266-5042","authenticated-orcid":true,"given":"Josephine","family":"Malinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimane","family":"Nekkab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-9649","authenticated-orcid":true,"given":"J\u00f6rg J.","family":"M\u00f6hrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-593X","authenticated-orcid":true,"given":"Melissa A.","family":"Penny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"9556","key":"pcbi.1014021.ref001","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(07)60076-2","article-title":"Child development: risk factors for adverse outcomes in developing countries","volume":"369","author":"SP Walker","year":"2007","journal-title":"Lancet"},{"key":"pcbi.1014021.ref002","unstructured":"World Health Organization. World Malaria Report 2025. Geneva: World Health Organization. 2025. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2025"},{"issue":"5","key":"pcbi.1014021.ref003","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa2112524","article-title":"Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania","volume":"386","author":"G Fink","year":"2022","journal-title":"N Engl J Med"},{"key":"pcbi.1014021.ref004","unstructured":"World Health Organization. WHO Guidelines for Malaria. https:\/\/app.magicapp.org\/#\/guideline\/7663 2023. 2024 June 5."},{"issue":"10265","key":"pcbi.1014021.ref005","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(20)32227-3","article-title":"Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study","volume":"396","author":"ACCESS-SMC Partnership","year":"2020","journal-title":"The Lancet"},{"issue":"1","key":"pcbi.1014021.ref006","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12936-022-04115-8","article-title":"Malaria chemoprevention and drug resistance: a review of the literature and policy implications","volume":"21","author":"CV Plowe","year":"2022","journal-title":"Malar J"},{"issue":"11","key":"pcbi.1014021.ref007","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","article-title":"Seasonal malaria vaccination with or without seasonal malaria chemoprevention","volume":"385","author":"D Chandramohan","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pcbi.1014021.ref008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","article-title":"Seasonal vaccination with RTS,S\/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial","volume":"24","author":"A Dicko","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pcbi.1014021.ref009","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12916-022-02536-5","article-title":"The duration of protection against clinical malaria provided by the combination of seasonal RTS,S\/AS01E vaccination and seasonal malaria chemoprevention versus either intervention given alone","volume":"20","author":"M Cairns","year":"2022","journal-title":"BMC Med"},{"issue":"10426","key":"pcbi.1014021.ref010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"MS Datoo","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"pcbi.1014021.ref011","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(22)00416-8","article-title":"Seasonal use case for the RTS,S\/AS01 malaria vaccine: a mathematical modelling study","volume":"10","author":"HA Thompson","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"17","key":"pcbi.1014021.ref012","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","article-title":"Subcutaneous administration of a monoclonal antibody to prevent malaria","volume":"390","author":"K Kayentao","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"pcbi.1014021.ref013","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.xcrm.2022.100786","article-title":"Accelerated development of malaria monoclonal antibodies","volume":"3","author":"N Nekkab","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"pcbi.1014021.ref014","first-page":"58","article-title":"Development of New Strategies for Malaria Chemoprophylaxis: From Monoclonal Antibodies to Long-Acting Injectable Drugs","volume":"7","author":"JJ Moehrle","year":"2022","journal-title":"Trop Med Infect Dis"},{"issue":"1","key":"pcbi.1014021.ref015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"JN Burrows","year":"2017","journal-title":"Malar J"},{"key":"pcbi.1014021.ref016","unstructured":"Medicines for Malaria Venture. MMV Annual Report 2022. 2023. https:\/\/www.mmv.org\/newsroom\/news-resources-search\/mmv-annual-report-2022"},{"issue":"1","key":"pcbi.1014021.ref017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41467-017-02603-z","article-title":"Long-acting injectable atovaquone nanomedicines for malaria prophylaxis","volume":"9","author":"RP Bakshi","year":"2018","journal-title":"Nat Commun"},{"issue":"674","key":"pcbi.1014021.ref018","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj3776","article-title":"A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria","volume":"14","author":"SB Sirima","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"pcbi.1014021.ref019","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1038\/s41467-024-48721-3","article-title":"Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex","volume":"15","author":"BG Williams","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1014021.ref020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","article-title":"Malaria vaccines since 2000: progress, priorities, products","volume":"5","author":"PE Duffy","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pcbi.1014021.ref021","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1038\/s41467-021-27486-z","article-title":"Emulator-based Bayesian optimization for efficient multi-objective calibration of an individual-based model of malaria","volume":"12","author":"T Reiker","year":"2021","journal-title":"Nat Commun"},{"key":"pcbi.1014021.ref022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4269\/tropmed.1999.61-044","article-title":"A retrospective examination of the patterns of recrudescence in patients infected with Plasmodium falciparum","volume":"61","author":"WE Collins","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"pcbi.1014021.ref023","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4269\/ajtmh.2006.75.19","article-title":"A model for natural immunity to asexual blood stages of Plasmodium falciparum malaria in endemic areas","volume":"75","author":"N Maire","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"pcbi.1014021.ref024","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4269\/ajtmh.2006.75.56","article-title":"An epidemiologic model of the incidence of acute illness in Plasmodium falciparum malaria","volume":"75","author":"T Smith","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pcbi.1014021.ref025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S0031182025000071","article-title":"A roadmap for understanding sulfadoxine-pyrimethamine in malaria chemoprevention","volume":"152","author":"T Masserey","year":"2025","journal-title":"Parasitology"},{"issue":"3","key":"pcbi.1014021.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000211","article-title":"Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention","volume":"2","author":"L Burgert","year":"2022","journal-title":"PLOS Glob Public Health"},{"issue":"8","key":"pcbi.1014021.ref027","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.04923-14","article-title":"Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso","volume":"59","author":"I Zongo","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pcbi.1014021.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0004549","article-title":"Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden","volume":"5","author":"J Malinga","year":"2025","journal-title":"PLOS Glob Public Health"},{"issue":"10016","key":"pcbi.1014021.ref029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","volume":"387","author":"MA Penny","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"pcbi.1014021.ref030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40249-022-00981-1","article-title":"Leveraging mathematical models of disease dynamics and machine learning to improve development of novel malaria interventions","volume":"11","author":"M Golumbeanu","year":"2022","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"pcbi.1014021.ref031","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00550-8","article-title":"Design and selection of drug properties to increase the public health impact of next-generation seasonal malaria chemoprevention: a modelling study","volume":"12","author":"L Braunack-Mayer","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"13","key":"pcbi.1014021.ref032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v098.i13","article-title":"hetGP: Heteroskedastic Gaussian Process Modeling and Sequential Design in R","volume":"98","author":"M Binois","year":"2021","journal-title":"J Stat Softw"},{"key":"pcbi.1014021.ref033","doi-asserted-by":"crossref","unstructured":"Sobol IM. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. Math Comput Sim. 2001;55(1\u20133):271\u201380.","DOI":"10.1016\/S0378-4754(00)00270-6"},{"key":"pcbi.1014021.ref034","unstructured":"Iooss B, Da Veiga S, Janon A, Pujol G. Global sensitivity analysis of model outputs. 2021."},{"key":"pcbi.1014021.ref035","unstructured":"R Core Team. R: A language and environment for statistical computing. https:\/\/www.R-project.org\/. 2021."},{"issue":"5","key":"pcbi.1014021.ref036","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S1473-3099(24)00752-7","article-title":"Safety and efficacy of the blood-stage malaria vaccine RH5.1\/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children","volume":"25","author":"HM Natama","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pcbi.1014021.ref037","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/s12936-021-03888-8","article-title":"Combining malaria vaccination with chemoprevention: a promising new approach to malaria control","volume":"20","author":"B Greenwood","year":"2021","journal-title":"Malar J"},{"issue":"1","key":"pcbi.1014021.ref038","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1186\/s12879-019-4467-4","article-title":"Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study","volume":"19","author":"F Camponovo","year":"2019","journal-title":"BMC Infect Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1014021","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1014021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:44:35Z","timestamp":1772736275000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1014021"}},"subtitle":[],"editor":[{"given":"Jennifer A.","family":"Flegg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1014021","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}